Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MRNA profiling of AGS Gastric Cancer cell line upon treatment with 5µM of Doxycycline

ABSTRACT: Doxycycline, a tetracycline based antibiotic which has bacteriostatic activity against a broad range of both gram positive and gram negative bacteria was identified to inhibit the expression of ERK/MAPK signaling pathway in gastric cancer. ERK/MAPK pathway is one of the highly activated and a crucial player in gastric cancer progression. To delineate the complex transcription program associated with ERK/MAPK pathway and thus inhibited by doxycycline in gastric cancer cells, doxycycline was treated in AGS, one of the ERK/MAPK overexpressed gastric cancer cell line. The resulatant changes in genome-wide mRNA expression pattern between control and doxycycline treated was profiled using Human Transcriptome 2.0 arrays.

ORGANISM(S): Homo sapiens

PROVIDER: GSE124022 | GEO | 2021/01/06

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Genome wide mRNA profiling of AGS, gastric cancer cell line upon treatment with 5µM of PD98059

Project description:ERK/MAPK pathway is one of the highly activated and a crucial player in gastric cancer proliferation and progression. To delineate the complex transcription program associated with ERK/MAPK pathway, PD98059 a known ERK/MAPK inhibitor was treated in AGS, one of the ERK/MAPK signaling pathway over expressed gastric cancer cell line. The resultant changes in genome-wide mRNA expression pattern between control and PD98059 treated was profiled using Human Gene 1.0 ST arrays.

2021-12-11 | GSE163545 | GEO

mRNA profiling of AGS Gastric Cancer cell line upon treatment with 5µM of Doxycycline

Project description:mRNA profiling of AGS Gastric Cancer cell line upon treatment with 5µM of Doxycycline

| PRJNA510586 | ENA

Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors

Project description:This is a Phase 1b/2, multi-center, open label umbrella study of patients ≥12 years of age with recurrent, progressive, or refractory melanoma or other solid tumors with alterations in the key proteins of the RAS/RAF/MEK/ERK pathway, referred to as the MAPK pathway.

| 2385126 | ecrin-mdr-crc

mRNA profiling of AGS gastric cancer cell line upon CTNNB1 silencing

Project description:Beta-catenin (CTNNB1) is a major component of Wnt signaling pathway and a crucial player in gastric cancer. To delineate the complex transcription program governed by CTNNB1 in gastric cancer cells, CTNNB1 was silenced in AGS, a commonly used Wnt signaling activated gastric cancer cell line and the resultant changes in genome-wide mRNA expression pattern was profiled using Affymetrix Human Gene 1.0 ST Array.

2015-12-01 | GSE61687 | GEO

Molecular Basis of Tropheryma whipplei Doxycycline Susceptibility Examined by Transcriptional Profiling

Project description:The suceptibility of T. whipplei to doxycycline was investigated at the transcriptional level using a whole-genome DNA microarray. The microarray data showed good agreement with real-time quantitative PCR (R = 0.969). Exposure of T. whipplei with the subinhibitory concentration of doxycycline allowed to observe antibiotic-specific primary expression profiles, while indirect effects were detected with a 10 times higher concencentration. In contrast to what was observed for several microorganisms exposed to antibiotics, the heat-shock proteins were not affected by the exposure of T. whipplei to doxycycline. Consistent with the mode of action of this translation inhibitor, genes encoding for ribosomal proteins and translation factors were differentially transcribed. This analysis also evidenced the regulation of genes that should account for the cell growth arrest. Long-term survival of nonreplicating bacteria is likely to be ensured by an increased level of ppGpp, the nucleotide effector of the stringent response. Gene expression profile to the higher concentrations of doxycycline was mainly characterized by the up-regulation of ABC transporters that possibly form efflux and detoxification systems, through which T. whipplei may limit the effects of this bacteriostatic compound. This work represents the first comprehensive genomic approach providing insight into the expression signature triggered by the exposure of this bacterial pathogen to antibiotics. Keywords: Antibiotic stress with Doxycycline

2006-09-07 | GSE5717 | GEO

AGS-RACK1

Project description:MicroRNA microarray profiling analysis was performed on human gastric cancer AGS cells after RACK1 silenced or not

2016-03-01 | E-MTAB-2619 | biostudies-arrayexpress

L-plastin Ser5 phosphorylation via RSKs, downstream effectors of the MAPK/ERK pathway, in (breast) cancer cells (and in vitro)

Project description:Deregulated cell migration and invasion, which are hallmarks of metastatic cancer cells, are correlated to structural and functional alterations of the actin cytoskeleton associated to a large panel of actin-binding proteins. Among these, the actin-bundling protein L-plastin, initially detected in leukocytes, is ectopically expressed in several solid tumours and is often considered as a metastatic marker. Phosphorylation of L-plastin on residue serine 5 (Ser5) has been shown to activate L-plastin and to be crucial for invasion and metastasis formation. Here, we investigate the signalling pathway leading to L-plastin Ser5 phosphorylation in four breast cancer cell lines. Whole genome microarray analysis comparing cell lines with different invasive capacities and corresponding L-plastin Ser5 phosphorylation levels revealed that genes of the MAPK/ERK pathway are differentially expressed. In line, in vitro kinase assays showed that MAPK/ERK pathway downstream kinases RSK1 and RSK2 are able to directly phosphorylate L-plastin on Ser5. In parallel to a knockdown approach, activation and inhibition studies of signalling molecules of the MAPK/ERK pathway, followed by computational modelling analysis, confirmed that RSK is an important activator of L-plastin in all four studied cell lines. Finally and rounding up our study, RSK knockdown significantly impaired migratory and invasive capacities of a selected invasive cell line, thus consolidating RSK as a promising therapeutic target in certain invasive carcinomas. Altogether, our data provide substantial evidence that the MAPK/ERK pathway is involved in L-plastin Ser5 phosphorylation in breast cancer cells with its downstream kinases RSK1 and RSK2 being able to directly phosphorylate L-plastin on Ser5.

2016-03-26 | E-MTAB-3487 | biostudies-arrayexpress

RNA-seq in AGS-EBV, shRNA

Project description:Gastric cancer is one of the most common cancers worldwide. Epstein-barr virus-associated gastric cancer accounts for about 10% of all gastric cancers. EBV itself expresses a variety of proteins and regulates the expression of host genes. In this study, we examined the knockdown of BC200 and eIF4A3 in AGS-EBV, respectively, and analyzed its effect on host mRNA expression.

2022-05-10 | GSE150299 | GEO

CircAkt3 participates in bone cancer pain progression in rats by modulating MAPK signalling pathway

Project description:CircRNA parent genes were mainly enriched in MAPK and neurodevelopmental signalling pathways. CircAkt3 and circMap4k1 were significantly up-regulated in the bone cancer pain group. CircaAkt3 may increase p-ERK expression by upregulating Col8a1, which may further activate the MAPK pathway.

2023-02-14 | GSE224978 | GEO

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Project description:The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations who have incomplete response to or have exhausted available therapies. Ulixertinib is available for treatment as monotherapy or in combination with other clinically tolerable agent(s), conditionally approved by the drug manufacturer.

| 2352905 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data